Yarlagadda S. Babu - Nov 14, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief Discovery Officer
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Nov 14, 2022
Transactions value $
-$295,428
Form type
4
Date filed
11/16/2022, 03:19 PM
Previous filing
Mar 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $71K +50K +21.73% $1.42* 280K Nov 14, 2022 Direct
transaction BCRX Common Stock Options Exercise $71K +50K +17.85% $1.42* 330K Nov 14, 2022 Direct
transaction BCRX Common Stock Sale -$437K -31.5K -9.55% $13.88 299K Nov 14, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -50K -100% $0.00* 0 Nov 14, 2022 Common Stock 50K $1.42 Direct F2
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -50K -100% $0.00* 0 Nov 14, 2022 Common Stock 50K $1.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2 Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date.
F3 Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date.